Rafferty Asset Management
TXMD icon

Rafferty Asset Management’s TherapeuticsMD TXMD Stock Holding History

Rafferty Asset Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,793
Closed -$107K – 1311
2021
Q2 		$107K Buy
1,793
+416
+30% +$25.2K ﹤0.01% 1247
2021
Q1 		$92K Buy
+1,377
New +$108K ﹤0.01% 1158
2020
Q2 		– Sell
-308
Closed -$16K – 998
2020
Q1 		$16K Sell
308
-601
-66% -$59.6K ﹤0.01% 593
2019
Q4 		$110K Buy
909
+209
+30% +$30.1K ﹤0.01% 861
2019
Q3 		$127K Buy
+700
New +$98.7K ﹤0.01% 789

Other funds holding TXMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rafferty Asset Management's TXMD Position: Q3 2021 in Review

Rafferty Asset Management sold out of TherapeuticsMD (TXMD) in Q3 2021, closing a stake of 1,793 shares — an estimated $107K sold.

Rafferty Asset Management first reported a position in TXMD in Q3 2019 and held it in 5 quarters. The position peaked at $127K in Q3 2019. 149 funds tracked by Wall St. Rank hold TXMD as of Q3 2021.

  • Rafferty Asset Management reported no remaining TherapeuticsMD position as of Q3 2021 after selling out during the quarter.
  • Rafferty Asset Management sold 1,793 TherapeuticsMD shares in Q3 2021, an estimated $107K.
  • Rafferty Asset Management first reported a position in TherapeuticsMD in Q3 2019 and held it in 5 quarters.
  • Rafferty Asset Management's TherapeuticsMD position peaked at $127K in Q3 2019.
  • 149 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2021.

Based on Rafferty Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.